Notably, patients with EIDA displayed a higher proportion of non-switched IgD+IgM+ memory B cells pre-AHSCT, suggesting a role for this subset in MS pathophysiology and highlighting its potential as a predictive biomarker for treatment response, though this needs confirmation in larger studies. The gene discussed is CD40LG; the disease is myeloid sarcoma.